Registry of Lobbyists

Registration - In-house Corporation

AstraZeneca Canada Inc. / Jane Chung, President

Registration Information

In-house Corporation name: AstraZeneca Canada Inc.
Responsible Officer Name: Jane Chung, President 
Responsible Officer Change History
Initial registration start date: 2007-03-08
Registration status: Active
Registration Number: 944875-15042

Associated Communications

Total Number of Communication Reports: 88

Monthly communication reports in the last 6 months: 1

Version 1 of 44 (2007-03-08 to 2007-09-20)

Version 1 of 44 (2007-03-08 to 2007-09-20) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, ON  L4Y 1M4
Canada
Telephone number: 905-566-7323
Fax number:  
Responsible officer name and position during the period of this registration: Mark Jones, President and CEO  
Description of activities: AstraZeneca Canada is the 2nd largest research-based pharmaceutical company in Canada. Our unique combination of curiosity and a fundamental commitment to patient health are the key drivers of research and development. Looking beyond the obvious and solving problems innovatively enables our scientists and the researchers we support to discover new and better treatments for a wide array of medical conditions and diseases. In Canada, we invest over CDN$2 million each and every week on research initiatives. Most of our 1,400 Canadian employees work at our high-tech facility in Mississauga, Ontario, headquarters for packaging, clinical research, sales and marketing, and distribution. Over 125 scientists work at our world-class basic pain research centre in Montréal, Québec (AZRDM), one of only three basic pain research facilities in Canada. AZRDM is a leader in pain control research, focusing primarily on the mechanisms involved in inflammatory and neuropathic pain, the two most common types of chronic pain. Our innovative and extensive product portfolio spans six therapeutic areas: cardiovascular, gastrointestinal, oncology, respiratory, neuroscience and infection.
 
The client is a subsidiary of the following parent companies: AstraZeneca PLC
15 Stanhope Gate
London W1K1LN
United Kingdom

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: Tara Bingham
Position title: Government Relations Manager - Federal
Public offices held: Yes
 
Name: William Charnetski
Position title: VP, Corporate Affairs and General Counsel
Public offices held: Yes
 
Name: Karen Feltmate
Position title: VP, Operations, Business Services & Regulatory Affairs
Public offices held: No
 
Name: Marie-Chantale Lepine
Position title: Director, Government Relations
Public offices held: Yes
 
Name: Alison Maloney
Position title: Director, Regulatory Affairs
Public offices held: No
 
Name: Martin McNeil
Position title: External Affairs Manager, Atlantic
Public offices held: No
 
Name: Steve Wilton
Position title: Executive Director, Patient Access, Reimbursement & Government Relations
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Aboriginal Affairs and Northern Development Canada, Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Environment Canada, Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), House of Commons, Industry Canada, Members of the House of Commons, National Defence (DND), National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Revenue Canada (RC), Royal Canadian Mounted Police (RCMP), Senate (Senators), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Aboriginal Affairs, Agriculture, Constitutional Issues, Consumer Issues, Environment, Health, Industry, Intellectual Property, Internal Trade, International Relations, International Trade, Justice and Law Enforcement, Regional Development, Science and Technology, Taxation and Finance
 
Subject Matter: Retrospective: Any legislative, regulatory, or policy proposals that would impact the research-based pharmaceutical industry including any changes to: drug patent legislation; health policies and programs; the national pharmaceutical strategy; cross-border drug trade; intellectual property protection; drug approvals, policies and processes; international trade policy as it relates to GATT/NAFTA/TRIPS; international aid; and industry policies.
Subject Matter: Prospective: Any legislative, regulatory, or policy proposals that would impact the research-based pharmaceutical industry including any changes to: drug patent legislation; health policies and programs; the national pharmaceutical strategy; cross-border drug trade; intellectual property protection; drug approvals, policies and processes; international trade policy as it relates to GATT/NAFTA/TRIPS; international aid; and industry policies.
 

Details Regarding the Identified Subject Matter

Categories Description
Legislative Proposal Budget/budget update
Policy or Program Canada's Access to Medicines Regime
Regulation Data Protection regulations
Policy or Program National Pharmaceutical Strategy (NPS)
Regulation Patented Medicines (Notice Of Compliance) regulations
Policy or Program Patented Medicines Price Review Board (PMPRB)
Policy or Program Science and Technology Strategy




Date Modified: